Holen Sie sich die Stockscreener-App
65.00
1.05%
-0.69
Handel nachbörslich:
65.29
0.29
+0.45%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ARWR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$65.69
Offen:
$67.32
24-Stunden-Volumen:
6.96M
Relative Volume:
2.78
Marktkapitalisierung:
$8.83B
Einnahmen:
$181.74M
Nettoeinkommen (Verlust:
$-143.97M
KGV:
-46.76
EPS:
-1.39
Netto-Cashflow:
$9.60M
1W Leistung:
-2.09%
1M Leistung:
-5.25%
6M Leistung:
+270.58%
1J Leistung:
+229.11%
1-Tages-Spanne:
$64.55
$69.42
1-Wochen-Bereich:
$60.62
$76.76
52-Wochen-Spanne:
$9.57
$76.76
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Firmenname
Arrowhead Pharmaceuticals Inc
Sektor
Branche
Telefon
626-696-4702
Adresse
177 E COLORADO BLVD, PASADENA, CA
Vergleichen Sie ARWR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
65.00 | 8.93B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-05 | Eingeleitet | Goldman | Neutral |
| 2023-12-04 | Eingeleitet | BofA Securities | Buy |
| 2023-09-19 | Eingeleitet | Citigroup | Neutral |
| 2023-07-21 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-12 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-12 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-11 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | Fortgesetzt | Goldman | Buy |
| 2021-08-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-11-19 | Eingeleitet | Citigroup | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-05-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-04-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | Eingeleitet | Goldman | Neutral |
| 2020-01-21 | Eingeleitet | SVB Leerink | Underperform |
| 2019-12-13 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-29 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-27 | Bestätigt | B. Riley FBR | Buy |
| 2019-11-25 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-10-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-09-07 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-08-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-07-02 | Bestätigt | Chardan Capital Markets | Buy |
Alle ansehen
Arrowhead Pharmaceuticals Inc Aktie (ARWR) Neueste Nachrichten
Can Arrowhead Pharmaceuticals Inc. stock surprise with earnings upsideShare Buyback & Risk Managed Investment Signals - ulpravda.ru
ARWR: Joint Management by Jefferies and JPMorgan in Recent Offering - GuruFocus
Arrowhead Pharmaceuticals prices upsize convertible notes offering to $625M and stock offering at $64.50 - MSN
Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants - BioSpace
Arrowhead Pharmaceuticals (ARWR) Unveils $625M Convertible Notes Offering - GuruFocus
Arrowhead Pharmaceuticals prices $625 million convertible notes offering - Investing.com
ARWR: Goldman Sachs Raises Arrowhead Pharma's Price Target to $8 - GuruFocus
Arrowhead Pharma (ARWR) Sees Target Price Boost by Morgan Stanley | ARWR Stock News - GuruFocus
Arrowhead Pharmaceuticals shares down 7.8% after co announces stock sale, convertible bond offering - MarketScreener
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China - BioSpace
Bernstein reiterates Market Perform rating on Arrowhead Pharma stock By Investing.com - Investing.com Canada
Arrowhead Pharmaceuticals (ARWR) Gains Approval in China for Red - GuruFocus
Arrowhead Pharma stock rating reiterated by Cantor Fitzgerald on obesity data - Investing.com Canada
Chardan Capital Raises Price Target for Arrowhead Pharma (ARWR) to $80.00 | ARWR Stock News - GuruFocus
Arrowhead (ARWR) Gains Approval in China for Redemplo - GuruFocus
Sanofi launches plozasiran in China following NMPA approval By Investing.com - Investing.com Australia
Sanofi launches plozasiran in China following NMPA approval - Investing.com
Arrowhead’s RNAi-based obesity drug combo shows benefit in Phase I/IIa trial - Clinical Trials Arena
Arrowhead Pharma stock holds steady as Goldman Sachs maintains Neutral rating - Investing.com Canada
Arrowhead Pharma stock price target raised to $84 from $81 at BofA - Investing.com UK
Arrowhead Pharmaceuticals plans to offer $700 million in securities By Investing.com - Investing.com Nigeria
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences - FinancialContent
Arrowhead Pharmaceuticals (ARWR) Surges on Promising Obesity The - GuruFocus
Arrowhead siRNA data in obesity mark POC for adipose delivery - BioCentury
Arrowhead (ARWR) Plans Convertible Notes and Stock Offerings - GuruFocus
Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock - TradingView — Track All Markets
Arrowhead Pharmaceuticals Shares Surge on Health Canada Approval - StocksToTrade
Arrowhead Shoots For Obesity With RNAi, Shows Weight Loss Success - Citeline News & Insights
Arrowhead Pharmaceuticals Announces Interim Results from Obesity Treatment Trials - TradingView — Track All Markets
Arrowhead Pharmaceuticals: A Closer Look at the Recent Stock Activity - StocksToTrade
Arrowhead Pharmaceuticals: More Questions Than Answers After Obesity Data Update - Seeking Alpha
Arrowhead (ARWR) Stock Gains from Promising Drug Trial Results - GuruFocus
Arrowhead stock leaps after gene-silencing obesity drug doubles Lilly’s Zepbound weight loss - ts2.tech
Arrowhead Pharmaceuticals Gains as Health Canada Approves Redemplo - timothysykes.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 52-Week HighTime to Buy? - MarketBeat
Arrowhead Enters Obesity Chat by Doubling Tirzepatide’s Weight Loss in Combo Study - BioSpace
Arrowhead Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:ARWR) - MarketBeat
Arrowhead Obesity Drugs Show Significant Fat Loss In Early Human Trials - Benzinga
Arrowhead Pharmaceuticals stock hits 52-week high at $72.95 By Investing.com - Investing.com Nigeria
Arrowhead’s RNAi trims fat in early PhI/IIa obesity data - The Pharma Letter
Arrowhead (ARWR) Reveals Promising Interim Results in Obesity Tr - GuruFocus
Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition - BioSpace
Arrowhead gains as obesity therapy doubles weight loss with Lilly’s Zepbound (ARWR:NASDAQ) - Seeking Alpha
Arrowhead stock soars after obesity drug shows doubled weight loss By Investing.com - Investing.com UK
Arrowhead Pharmaceuticals announces interim clinical data on RNAi-based obesity candidates - MarketScreener
Arrowhead receives Health Canada authorisation for Redemplo to treat FCS - Yahoo Finance
Arrowhead Pharma Shares in Focus After $2.5M Insider Sale - Eudaimonia and Co
Arrowhead Pharmaceuticals (ARWR) Is Down 5.0% After First-in-Class FCS siRNA Approval in Canada - Yahoo Finance
Arrowhead Pharmaceuticals (NASDAQ:ARWR) COO Sells $3,123,503.23 in Stock - MarketBeat
Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) CEO Sells 13,187 Shares of Stock - MarketBeat
Arrowhead Pharma COO O’Brien sells $3.1m in shares By Investing.com - Investing.com Nigeria
Finanzdaten der Arrowhead Pharmaceuticals Inc-Aktie (ARWR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
4.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):